The Technical Analyst
DexCom Inc [DXCM]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
DexCom Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.67% $130.71
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 50 391 mill |
| EPS: | 1.300 |
| P/E: | 100.55 |
| Earnings Date: | Apr 24, 2024 |
| SharesOutstanding: | 385.52 mill |
| Avg Daily Volume: | 3.05 mill |
| RATING 2024-04-19 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 100.55 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.45x |
| Company: PE 100.55 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$29.39 (-77.52%) $-101.32 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 126.69 - 134.73 ( +/- 3.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Dolan Matthew Vincent | Sell | 1 990 | Common Stock |
| 2024-04-08 | Sayer Kevin R | Sell | 27 272 | Common Stock |
| 2024-04-08 | Sayer Kevin R | Sell | 22 361 | Common Stock |
| 2024-03-28 | Brown Michael Jon | Sell | 2 524 | Common Stock |
| 2024-03-28 | Brown Michael Jon | Sell | 100 | Common Stock |
| INSIDER POWER |
|---|
| -3.98 |
| Last 99 transactions |
| Buy: 330 077 | Sell: 354 468 |
Forecast:
16:00 - $130.77
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $130.77
Forecast 2: 16:00 - $130.77
Forecast 3: 16:00 - $130.77
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $130.71 (-2.67% ) |
| Volume | 2.85 mill |
| Avg. Vol. | 3.05 mill |
| % of Avg. Vol | 93.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DXCM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $126.59 | N/A | Active |
|---|
DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Latest Press Releases
2024-04-10 10:19:00 - Press Release
Md Revolution Partners With Dexcom To Integrate Continuous Glucose Monitoring Systems With Its Remote Care Management Platform
San diego--(business wire)--md revolution, the leader in remote care management solutions for health systems and multi-specialty clinics, has partnered with dexcom to integrate their industry-leading continuous glucose monitoring systems with md revolution's remote care management platform. over 537 million people globally are living with diabetes. dexcom supports this population as a global leader in real-time continuous glucose monitoring. dexcom's wearable devices pair with a user's smartpho.
2024-04-03 09:00:00 - Press Release
Dexcom Publishes Annual Sustainability Report
San diego--(business wire)--dexcom, inc. (nasdaq:dxcm), the leader in real-time continuous glucose monitoring (cgm) for people with diabetes, today released its annual sustainability report. this report provides updates on key corporate sustainability initiatives that are aligned with dexcom's core values and business strategy. “we are always working to advance the interests of our stakeholders, including our global customer base, employees and their families, caregivers, our communities, and o.
2024-04-02 08:30:00 - Press Release
Dexcom Schedules First Quarter 2024 Earnings Release And Conference Call For April 25, 2024 At 4:30 P.m. Eastern Time
San diego--(business wire)--dexcom, inc. (nasdaq:dxcm) today announced that it plans to release its first quarter 2024 financial results after market close on thursday, april 25, 2024. management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (eastern time) on the same day. the conference call will be concurrently webcast. the link to the webcast will be available on the dexcom investor relations website at investors.dexcom.com and will.
2024-03-05 16:26:00 - Press Release
Stelo By Dexcom First Glucose Biosensor To Be Cleared By Fda As Over-the-counter
San diego--(business wire)--dexcom, inc. (nasdaq:dxcm), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the fda has cleared stelo by dexcom – the first glucose biosensor that doesn't require a prescription. there are approximately 25 million people in the u.s. living with type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (cgm) technology. today, dexcom g7 is available for them with a prescrip.
2024-03-05 03:00:00 - Press Release
Dexcom Showcases Leadership In Aid And Power Of Dexcom Cgm In Type 2 Diabetes With New Data At Attd
Edinburgh, scotland--(business wire)--dexcom, inc. (nasdaq: dxcm), the global leader in real-time continuous glucose monitoring (cgm) for people with diabetes, announced compelling new clinical evidence supporting the use of dexcom continuous glucose monitoring (cgm) for automated insulin delivery (aid) systems. dexcom also announced data showcasing the significant benefits of cgm use for individuals managing type 2 diabetes, along with groundbreaking evidence demonstrating a direct association.
Latest News
2024-04-18 09:31:10 - Zacks Investment Research
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
2024-04-15 12:21:06 - Zacks Investment Research
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.
2024-04-15 11:56:14 - Zacks Investment Research
DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
2024-04-11 14:22:30 - Schwab Network
SLB, DXCM, CRH: The Economy is Relatively Healthy
Economic trends and earnings continue to drive most of the conversations, notes Tyler Ellegard. He discusses the impact upcoming earnings could have on the markets.
2024-04-11 10:46:34 - Zacks Investment Research
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
2024-04-11 09:02:57 - Seeking Alpha
DexCom Is Pricey For A Reason - Its Growth Story Reflects That
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust growth in revenue and operating income, warranting its high valuation multiples. DexCom has strong growth catalysts, including the launch of Stelo, which is expected to contribute to significant revenue growth in the future.
2024-04-10 16:00:00 - InvestorPlace
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain cautious of the Fed's stance on interest rate adjustments.
2024-04-10 09:27:00 - Market Watch
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
2024-04-08 19:06:03 - Zacks Investment Research
Why the Market Dipped But DexCom (DXCM) Gained Today
In the most recent trading session, DexCom (DXCM) closed at $139.94, indicating a +0.73% shift from the previous trading day.
2024-04-04 10:01:03 - Zacks Investment Research
DexCom, Inc. (DXCM) is Attracting Investor Attention: Here is What You Should Know
DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.